Scholarlink

Background <p>The standard treatment for unresectable non-small cell lung cancer (NSCLC) is anti-PD-L1 therapy combined with chemoradiotherapy (anti-PD-L1-CRT). Although some patients achieve complete cancer eradication and cure, more than half of patients retain persistent cancer cells. Our research aimed to unravel the nuanced mechanisms involved in both immune attack and evasion induced by anti-PD-L1-CRT with single cell spatial transcriptome.</p> Methods <p>Xenium is a cutting-edge single-cell spatial analysis tool that enables pathology-based and single-cell analyses while preserving spatial information. In our study, we used Xenium to identify the tumour microenvironment (TME), immune dynamics, and residual cancer cells at the single-cell level following treatment with anti-PD-L1-CRT.</p> Results <p>Posttreatment alterations included a significant increase in <i>CXCL9</i>+ cells and <i>CXCL13</i> + T cells, particularly around tumour cells. Additionally, we discovered that <i>CXCL13</i> + T cells directly impact cancer cells in the posttreatment environment. Moreover, we identified clusters of immune-cold cancer cells posttreatment, revealing their activation of DNA repair pathways and high proliferative capacity. The novel spatial analysis tool Xenium enabled identification of the immune environment at the single-cell level following treatment with anti-PD-L1-CRT, elucidating its characteristics.</p> Conclusions <p>These findings suggest potential advancements in developing new treatments to improve posttreatment immune responses and address resistance challenges.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月16日

查看全文
  • Shunsuke A. Sakai,
  • Hidekazu Oyoshi,
  • Masaki Nakamura,
  • Tetsuro Taki,
  • Kotaro Nomura,
  • Hidehiro Hojo,
  • Hidenari Hirata,
  • Atsushi Motegi,
  • Yuka Nakamura,
  • Junko Zenkoh,
  • Keiju Aokage,
  • Akira Hamada,
  • Motohiro Kojima,
  • Takeshi Kuwata,
  • Katsuya Tsuchihara,
  • Tetsuo Akimoto,
  • Junichi Soh,
  • Tetsuya Mitsudomi,
  • Masahiro Tsuboi,
  • Genichiro Ishii,
  • Yutaka Suzuki,
  • Ayako Suzuki,
  • Riu Yamashita,
  • Shun-Ichiro Kageyama

摘要

Background

The standard treatment for unresectable non-small cell lung cancer (NSCLC) is anti-PD-L1 therapy combined with chemoradiotherapy (anti-PD-L1-CRT). Although some patients achieve complete cancer eradication and cure, more than half of patients retain persistent cancer cells. Our research aimed to unravel the nuanced mechanisms involved in both immune attack and evasion induced by anti-PD-L1-CRT with single cell spatial transcriptome.

Methods

Xenium is a cutting-edge single-cell spatial analysis tool that enables pathology-based and single-cell analyses while preserving spatial information. In our study, we used Xenium to identify the tumour microenvironment (TME), immune dynamics, and residual cancer cells at the single-cell level following treatment with anti-PD-L1-CRT.

Results

Posttreatment alterations included a significant increase in CXCL9+ cells and CXCL13 + T cells, particularly around tumour cells. Additionally, we discovered that CXCL13 + T cells directly impact cancer cells in the posttreatment environment. Moreover, we identified clusters of immune-cold cancer cells posttreatment, revealing their activation of DNA repair pathways and high proliferative capacity. The novel spatial analysis tool Xenium enabled identification of the immune environment at the single-cell level following treatment with anti-PD-L1-CRT, elucidating its characteristics.

Conclusions

These findings suggest potential advancements in developing new treatments to improve posttreatment immune responses and address resistance challenges.